{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-129380","form_type":"8-K","ticker":"DLB","cik":"0001308547","company_name":"Dolby Laboratories, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.787993+00:00","generated_at":"2026-06-03T00:05:39.133841+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dolby Q2 FY2024 revenue $364.5M (-3% YoY); GAAP EPS $1.01, non-GAAP $1.27","bullets":["Revenue $364.5M vs $375.9M YoY; GAAP net income $97.8M ($1.01/diluted share) vs $95.7M ($0.98) YoY.","Non-GAAP net income $123.2M ($1.27/diluted) vs $122.6M ($1.26) YoY.","Q3 FY2024 revenue guidance $270M–$300M; full-year FY2024 revenue ~$1.30B.","Q3 GAAP diluted EPS guidance $0.21–$0.36; non-GAAP $0.51–$0.66.","Declared cash dividend $0.30/share payable May 22, 2024 to holders of record May 14, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-129380","json":"https://secwatch.observer/filing/0001193125-24-129380.json","markdown":"https://secwatch.observer/filing/0001193125-24-129380.md","text":"https://secwatch.observer/filing/0001193125-24-129380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1308547/000119312524129380/0001193125-24-129380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1308547/000119312524129380/d823706d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:05:39.133841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"637dfc3bce8f69a3d2051b872dec8bc6396132c8","claim":"Dolby Laboratories, Inc. reported third quarter of fiscal 2024 and full year of fiscal 2024 results: EPS $0.21 to $0.36 on a GAAP basis and from $0.51 to $0.66 on a non-GAAP basis for Q3; $2.30 to $2.45 on a GAAP basis and fr. Guidance reaffirmed.","evidence_excerpt":"Total revenue is estimated to range from $270 million to $300 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1308547/000119312524129380/0001193125-24-129380-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of fiscal 2024 and full year of fiscal 2024"},{"label":"EPS","value":"$0.21 to $0.36 on a GAAP basis and from $0.51 to $0.66 on a non-GAAP basis for Q3; $2.30 to $2.45 on a GAAP basis and fr"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}]},{"claim_id":"8d5100516b6ecf05a218a135a88eda33aeef5136","claim":"Dolby Laboratories, Inc. reported second quarter of fiscal 2024 results: revenue $364.5 million, net income $97.8 million, EPS $1.01 per diluted share. Guidance reaffirmed.","evidence_excerpt":"sports, music and more, driving more consumer device adoption and bringing Dolby to more people worldwide.” Second Quarter Fiscal 2024 Financial Highlights • Total revenue was $364.5 million, compared to $375.9 million for the second quarter of fiscal 2023. • GAAP net income was $97.8 million, or $1.01 per diluted share, compared to GAAP net income of $95.7 million,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1308547/000119312524129380/0001193125-24-129380-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of fiscal 2024"},{"label":"Revenue","value":"$364.5 million"},{"label":"Net income","value":"$97.8 million"},{"label":"EPS","value":"$1.01 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}